Q4 2025 Lymphoma & Leukemia Market: Regulatory Milestones, ASH 2025 Data, and Evolving Treatment Strategies

Bristol Myers Squibb highlighted the FDA’s approval of Breyanzi for heavily pre-treated MZL, shared new data at ASH 2025, and premiered a new DTC campaign theme.

BeOne Medicines featured Brukinsa’s landmark results in CLL at ASH 2025 and provided transition guidance for its new, more convenient formulation.

AstraZeneca announced an upcoming combination regimen of Calquence with venetoclax and featured multiple presentations at ASH 2025 on B-cell malignancies.

Johnson & Johnson presented fixed-duration regimen outcomes with Imbruvica and announced a cost adjustment for 2026.

Lilly expanded regulatory momentum with Jaypirca’s new CLL/SLL indication and shared positive data from a first-of-its-kind head-to-head trial at ASH 2025.

Genentech announced FDA approval of a Lunsumio subcutaneous formulation, offering a more time-efficient care option.

AbbVie promoted the premiere of a short film it supported about the personal experiences of those living with CLL.